SOUTH SAN FRANCISCO, Calif., Oct. 31, 2018 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a
clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor
metabolism and tumor immunology targets for the treatment of cancer, today announced that the Company’s third quarter 2018
financial results will be released on Wednesday, November 7, 2018. Company management will host a conference call on Wednesday,
November 7, 2018 at 2:00 p.m. Pacific Time/ 5:00 p.m. Eastern Time to discuss the financial results and other recent corporate
highlights.
The press release and live audio webcast can be accessed via the Investor section of the Company’s website at
www.calithera.com. The conference call can be accessed by dialing (855) 783-2599 (domestic) or
(631) 485-4877 (international) and refer to conference ID 9368596. Please log in approximately 5-10 minutes before the event to
ensure a timely connection. The archived webcast will remain available for replay on Calithera’s website for 30 days.
About Calithera
Calithera is a clinical-stage biopharmaceutical company focused on fighting cancer by discovering, developing, and
commercializing novel small molecule drugs that target tumor and immune cell metabolism. Calithera is headquartered in South San
Francisco, California. For more information about Calithera, please visit www.calithera.com.
Forward Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking
statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect,"
"anticipate," "estimate," "intend," "poised" and similar expressions (as well as other words or expressions referencing future
events, conditions, or circumstances) are intended to identify forward-looking statements. These statements include those related
to the safety, tolerability and efficacy of Calithera’s product candidates, the overall advancement of Calithera’s product
candidates in clinical trials, the unmet need in the treatment of patients with advanced disease, and Calithera’s plans to continue
development of its product candidates. Because such statements are subject to risks and uncertainties, actual results may differ
materially from those expressed or implied by such forward-looking statements. The product candidates that Calithera develops may
not progress through clinical development or receive required regulatory approvals within expected timelines or at all. In
addition, clinical trials may not confirm any safety, potency or other product characteristics described or assumed in this press
release. Such product candidates may not be beneficial to patients or successfully commercialized. The failure to meet expectations
with respect to any of the foregoing matters may have a negative effect on Calithera's stock price. Additional information
concerning these and other risk factors affecting Calithera's business can be found in Calithera's most recent Quarterly Report on
Form 10-Q filed with the Securities and Exchange Commission, and other periodic filings with the Securities and Exchange Commission
at www.sec.gov. These forward-looking statements are not guarantees of future performance and speak only as of the date hereof,
and, except as required by law, Calithera disclaims any obligation to update these forward-looking statements to reflect future
events or circumstances.
SOURCE: Calithera Biosciences, Incorporated
CONTACT:
Jennifer McNealey
ir@Calithera.com
650-870-1071
